GlobeNewsWire
10 Jun 2026, 10:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Culper Research alleges ADMA Biologics used a channel stuffing scheme to report 20% revenue growth in 2025, whereas real growth was allegedly -3%. — Allegations of fraudulent financial reporting and artificial revenue inflation fundamentally undermine company valuation and investor trust.
-0.90Law firm Bleichmar Fonti & Auld is investigating ADMA Biologics for potential violations of federal securities laws following a 29% stock price drop. — The initiation of a legal investigation by a leading securities firm increases the likelihood of a class-action lawsuit and further regulatory scrutiny.
-0.60Which stocks this story touches
The company is under investigation for securities fraud and alleged channel stuffing, leading to a 29% stock price drop.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is being investigated for misrepresenting its pricing issues.
The company is being investigated for misrepresenting its membership growth issues.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
2h ago
